source
- #ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that goodCHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News. “H…Endpoints · 2mo ago↗ source
- #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer studyCHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…Endpoints · 2mo ago↗ source
- Akeso, Summit drug extends survival in closely watched lung cancer trialThough ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.